Veracyte/$VCYT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Veracyte

Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.

Ticker

$VCYT
Sector
Primary listing

Employees

824

Veracyte Metrics

BasicAdvanced
$2.4B
91.22
$0.34
1.97
-

What the Analysts think about Veracyte

Analyst ratings (Buy, Hold, Sell) for Veracyte stock.

Bulls say / Bears say

Veracyte’s Decipher prostate cancer test posted its thirteenth straight quarter with over 25% year-over-year volume growth, rising 28% in Q2 2025, demonstrating continued strong demand for the company’s key test (Reuters).
Total revenue for Q2 2025 grew 14% year-over-year to $130.2 million, surpassing analyst estimates. As a result, Veracyte raised its full-year testing revenue guidance to $477 million–$483 million and issued total revenue guidance of $496 million–$504 million (Reuters).
Adjusted EBITDA in Q2 2025 jumped 49% year-over-year to $35.8 million, accounting for 27.5% of revenue versus 21.0% last year, indicating enhanced operating efficiency and wider margins (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.

Veracyte Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Veracyte Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $VCYT

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs